PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Canadian Man Jailed After Referring to Biological Daughter by Wrong Pronoun

Show Me

Iowa University Officials Denied Immunity for Targeting Christian Student Group

Show Me

Scotland Passes Hate Crime Law Amid Free Speech Concerns

Show Me

Fresh hope for campus free speech

Show Me

Rallies for Freedom, Peace and Democracy Planned in 40+ Countries

Show Me

Commentary: Your Freedom of Speech Ends Wednesday

Show Me

RE teacher suspended over Prophet Muhammad cartoon ‘defended his right to freedom of speech’

Show Me

Award-Winning Biologist Slams Peter Daszak And WHO COVID Colleagues For Peddling Chinese Communist Party ‘Disinformation.’

Show Me

California theme parks instruct visitors to stay silent on roller coasters to stem COVID-19 spread

Show Me

Colorado loosens COVID restrictions across most of state in major — and likely final — revision of dial

Show Me

Loretto Hospital executive resigns in wake of COVID-19 vaccination scandal

Show Me

No Surge in COVID Two Weeks After Mask Mandate Lifted in Texas

Show Me

Judicial Watch Sues for Records of New York, Pennsylvania COVID-19 Nursing Homes Policies

Show Me

Smokers prioritized for COVID-19 vaccine shots by CDC and Gov. J.B. Pritzker — not by Chicago (LIVE UPDATES)

Show Me

CDC Director Warns of Possible ‘Avoidable Surge’ in Covid Cases

Show Me

Ex CDC director Robert Redfield believes COVID ‘escaped’ from Wuhan lab as early as September 2019

Show Me

Compromised Fauci quick to throw cold water on former CDC chief’s announcement he believes covid escaped from Wuhan lab

Show Me

68-Year-Old Dies After Anaphylactic Reaction to COVID Vaccine as CDC Continues to Ignore Inquiry Into Increasing Number of Deaths

Show Me

Former CDC Director: COVID-19 Escaped From Wuhan Virology Lab

Show Me

Japan rejects China’s offer to provide COVID vaccines for athletes in upcoming Olympic games

Show Me

China’s deception over COVID-19’s origins gets more outrageous every day

Show Me

Pope, citing pandemic effect, cuts pay for cardinals, others

Show Me

Commentary: The Nature of Chinese Communist Party’s Contempt for Us

Show Me

Sinopharm Chairman Claims He Received COVID-19 Vaccine One Year Ago, Has Antibodies

Show Me

Happiness Report: World shows resilience in face of COVID19

Show Me

Judicial Watch Sues for NIH Funding and Other Records Tied to China’s Wuhan Institute of Virology

Show Me

1 report, 4 theories: Scientists mull clues on origin of COVID-19

Show Me

China’s COVID-19 Timeline Questioned After Official Claims to Be Vaccinated in March 2020

Show Me

Before COVID Outbreak, Gates Planned Social Media Censorship of Vaccine Safety Advocates With Pharma, CDC, Media, China and CIA

Show Me

WHO Delays Report On COVID’s Origins As China ‘Fights Tooth & Nail Over Each Sentence,’ WHO Advisor Says

Show Me

China Bans UK MPs Over Uyghur Sanctions

Show Me

Did the coronavirus leak from a lab? These scientists say we shouldn’t rule it out.

Show Me

Biden Under Investigation For Breaking The Law Through Executive Orders

Show Me

Most Americans Are Thinking, “Of Course” | “Biden For President 2020” flag flies in Tijuana camp as migrants wait to cross US-Mexico border

Show Me

Sex offenders and MS-13 members caught after illegally crossing the southern border

Show Me

Biden, Not Trump, Driving Border Crisis

Show Me

Former CBP Commissioner: Biden admin’s border policies are ‘against the nation’s best interest’

Show Me

LIVE: Talk with Mike Pompeo: China on the Move & the Breakdown at the Border

Show Me

Lovers Of Falsehoods Must Be Head Over Heels With Jack Dorsey, Big Tech & Big Business | Twitter admits error by censoring photos of detention center at US-Mexico border

Show Me

Hundreds of migrant children detained at border have tested positive for COVID-19: report

Show Me